{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,14]],"date-time":"2025-12-14T17:05:22Z","timestamp":1765731922195,"version":"3.40.4"},"reference-count":65,"publisher":"Public Library of Science (PLoS)","issue":"1","license":[{"start":{"date-parts":[[2014,1,27]],"date-time":"2014-01-27T00:00:00Z","timestamp":1390780800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0086299","type":"journal-article","created":{"date-parts":[[2014,1,27]],"date-time":"2014-01-27T21:29:34Z","timestamp":1390858174000},"page":"e86299","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":36,"title":["Functional Module Connectivity Map (FMCM): A Framework for Searching Repurposed Drug Compounds for Systems Treatment of Cancer and an Application to Colorectal Adenocarcinoma"],"prefix":"10.1371","volume":"9","author":[{"given":"Feng-Hsiang","family":"Chung","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yun-Ru","family":"Chiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ai-Lun","family":"Tseng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yung-Chuan","family":"Sung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Min-Chang","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nianhan","family":"Ma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hoong-Chien","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2014,1,27]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1007\/BF03256811","article-title":"Repurposing Strategies for Therapeutics","volume":"24","author":"SH Sleigh","year":"2010","journal-title":"Pharmaceutical Medicine"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1038\/nrd2155","article-title":"Why is cancer drug discovery so difficult?","volume":"6","author":"A Kamb","year":"2007","journal-title":"Nat Rev Drug Discov"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1038\/448645a","article-title":"New uses for old drugs","volume":"448","author":"CR Chong","year":"2007","journal-title":"Nature"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"177","DOI":"10.2174\/157488607781668855","article-title":"Drug withdrawals in the United States: a systematic review of the evidence and analysis of trends","volume":"2","author":"AM Issa","year":"2007","journal-title":"Curr Drug Saf"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"15","DOI":"10.2165\/11598420-000000000-00000","article-title":"Psychotropic Drug-Induced Falls in Older People A Review of Interventions Aimed at Reducing the Problem","volume":"29","author":"KD Hill","year":"2012","journal-title":"Drugs & Aging"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1002\/pds.1207","article-title":"A systematic review of NSAIDs withdrawn from the market due to hepatotoxicity: lessons learned from the bromfenac experience","volume":"15","author":"L Goldkind","year":"2006","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1038\/nrd2132","article-title":"Opinion - Drugs, their targets and the nature and number of drug targets","volume":"5","author":"P Imming","year":"2006","journal-title":"Nature Reviews Drug Discovery"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1016\/j.drudis.2010.06.006","article-title":"Drug profiling: knowing where it hits","volume":"15","author":"A Merino","year":"2010","journal-title":"Drug Discov Today"},{"key":"ref9","first-page":"1446","article-title":"The war on cancer: An anatomy of failure, a blueprint for the future","volume":"25","author":"RA Rettig","year":"2006","journal-title":"Health Affairs"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1093\/carcin\/bgp261","article-title":"Cancer systems biology: a network modeling perspective","volume":"31","author":"PK Kreeger","year":"2010","journal-title":"Carcinogenesis"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of cancer: the next generation","volume":"144","author":"D Hanahan","year":"2011","journal-title":"Cell"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1038\/nrd2826","article-title":"A network view of disease and compound screening","volume":"8","author":"EE Schadt","year":"2009","journal-title":"Nat Rev Drug Discov"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"2466","DOI":"10.1093\/bioinformatics\/btp465","article-title":"Network analyses in systems pharmacology","volume":"25","author":"SI Berger","year":"2009","journal-title":"Bioinformatics"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1038\/nchembio.118","article-title":"Network pharmacology: the next paradigm in drug discovery","volume":"4","author":"AL Hopkins","year":"2008","journal-title":"Nat Chem Biol"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.biosystems.2005.05.014","article-title":"Cancer: a Systems Biology disease","volume":"83","author":"JJ Hornberg","year":"2006","journal-title":"Biosystems"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1208\/s12248-012-9390-1","article-title":"Drug repurposing: far beyond new targets for old drugs","volume":"14","author":"TI Oprea","year":"2012","journal-title":"AAPS J"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1126\/science.1132939","article-title":"The Connectivity Map: using gene-expression signatures to connect small molecules, genes, and disease","volume":"313","author":"J Lamb","year":"2006","journal-title":"Science"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"19432","DOI":"10.1073\/pnas.0806674105","article-title":"A genomic approach to colon cancer risk stratification yields biologic insights into therapeutic opportunities","volume":"105","author":"KS Garman","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"e22274","DOI":"10.1371\/journal.pone.0022274","article-title":"An integrated bioinformatics approach identifies elevated cyclin E2 expression and E2F activity as distinct features of tamoxifen resistant breast tumors","volume":"6","author":"L Huang","year":"2011","journal-title":"PLoS One"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"e14573","DOI":"10.1371\/journal.pone.0014573","article-title":"Expression-based in silico screening of candidate therapeutic compounds for lung adenocarcinoma","volume":"6","author":"G Wang","year":"2011","journal-title":"PLoS One"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"96ra76","DOI":"10.1126\/scitranslmed.3002648","article-title":"Computational repositioning of the anticonvulsant topiramate for inflammatory bowel disease","volume":"3","author":"JT Dudley","year":"2011","journal-title":"Sci Transl Med"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"96ra77","DOI":"10.1126\/scitranslmed.3001318","article-title":"Discovery and preclinical validation of drug indications using compendia of public gene expression data","volume":"3","author":"M Sirota","year":"2011","journal-title":"Sci Transl Med"},{"key":"ref23","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pcbi.1002347","article-title":"Using Functional Signatures to Identify Repositioned Drugs for Breast, Myelogenous Leukemia and Prostate Cancer","volume":"8","author":"D Shigemizu","year":"2012","journal-title":"Plos Computational Biology"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"ra31","DOI":"10.1126\/scisignal.2000352","article-title":"Therapeutically targeting ErbB3: a key node in ligand-induced activation of the ErbB receptor-PI3K axis","volume":"2","author":"B Schoeberl","year":"2009","journal-title":"Sci Signal"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1124\/mol.107.043794","article-title":"Multipathway model enables prediction of kinase inhibitor cross-talk effects on migration of Her2-overexpressing mammary epithelial cells","volume":"73","author":"N Kumar","year":"2008","journal-title":"Mol Pharmacol"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"e65683","DOI":"10.1371\/journal.pone.0065683","article-title":"ToP: A Trend-of-Disease-Progression Procedure Works Well for Identifying Cancer Genes from Multi-State Cohort Gene Expression Data for Human Colorectal Cancer","volume":"8","author":"FH Chung","year":"2013","journal-title":"PLoS One"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1158\/1541-7786.MCR-07-0267","article-title":"Transcriptome profile of human colorectal adenomas","volume":"5","author":"J Sabates-Bellver","year":"2007","journal-title":"Mol Cancer Res"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"D767","DOI":"10.1093\/nar\/gkn892","article-title":"Human Protein Reference Database\u20132009 update","volume":"37","author":"TS Keshava Prasad","year":"2009","journal-title":"Nucleic Acids Res"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1038\/75556","article-title":"Gene ontology: tool for the unification of biology. The Gene Ontology Consortium","volume":"25","author":"M Ashburner","year":"2000","journal-title":"Nature genetics"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"D1128","DOI":"10.1093\/nar\/gkr797","article-title":"Therapeutic target database update 2012: a resource for facilitating target-oriented drug discovery","volume":"40","author":"F Zhu","year":"2012","journal-title":"Nucleic Acids Res"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"15545","DOI":"10.1073\/pnas.0506580102","article-title":"Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles","volume":"102","author":"A Subramanian","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"5116","DOI":"10.1073\/pnas.091062498","article-title":"Significance analysis of microarrays applied to the ionizing radiation response","volume":"98","author":"VG Tusher","year":"2001","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1093\/bioinformatics\/btl140","article-title":"Improved scoring of functional groups from gene expression data by decorrelating GO graph structure","volume":"22","author":"A Alexa","year":"2006","journal-title":"Bioinformatics"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1093\/biostatistics\/4.2.249","article-title":"Exploration, normalization, and summaries of high density oligonucleotide array probe level data","volume":"4","author":"RA Irizarry","year":"2003","journal-title":"Biostatistics"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"Article3","DOI":"10.2202\/1544-6115.1027","article-title":"Linear models and empirical bayes methods for assessing differential expression in microarray experiments","volume":"3","author":"GK Smyth","year":"2004","journal-title":"Stat Appl Genet Mol Biol"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1038\/nprot.2008.211","article-title":"Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources","volume":"4","author":"W Huang da","year":"2009","journal-title":"Nat Protoc"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1016\/S0140-6736(00)02034-1","article-title":"Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial","volume":"355","author":"JY Douillard","year":"2000","journal-title":"Lancet"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1007\/BF01788366","article-title":"Use of thapsigargin to study Ca2+ homeostasis in cardiac cells","volume":"15","author":"TB Rogers","year":"1995","journal-title":"Bioscience Reports"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1182\/blood.V13.12.1126.1126","article-title":"A comparative study of two regimens of combination chemotherapy in acute leukemia","volume":"13","author":"E Frei 3rd","year":"1958","journal-title":"Blood"},{"key":"ref40","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1038\/sj.sc.3101789","article-title":"Chronic lymphocytic leukaemia, synchronous small cell carcinoma and squamous neoplasia of the urinary bladder in a paraplegic man following long-term phenoxybenzamine therapy","volume":"44","author":"S Vaidyanathan","year":"2006","journal-title":"Spinal Cord"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.mrrev.2005.12.002","article-title":"Genotoxicity and carcinogenicity studies of antihypertensive agents","volume":"612","author":"G Brambilla","year":"2006","journal-title":"Mutat Res"},{"key":"ref42","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1023\/A:1017972622312","article-title":"Inhibitory effects of extracellular Mg2+ on intracellular Ca2+ dynamic changes and thapsigargin-induced apoptosis in human cancer MCF7 cells","volume":"229","author":"M Pereira","year":"2002","journal-title":"Mol Cell Biochem"},{"key":"ref43","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1002\/1097-0045(20000601)43:4<303::AID-PROS10>3.0.CO;2-V","article-title":"Thapsigargin induces a calmodulin\/calcineurin-dependent apoptotic cascade responsible for the death of prostatic cancer cells","volume":"43","author":"B Tombal","year":"2000","journal-title":"Prostate"},{"key":"ref44","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1002\/(SICI)1097-0045(19971101)33:3<201::AID-PROS9>3.0.CO;2-L","article-title":"Mechanism and role of growth arrest in programmed (apoptotic) death of prostatic cancer cells induced by thapsigargin","volume":"33","author":"XS Lin","year":"1997","journal-title":"Prostate"},{"key":"ref45","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1007\/BF00389230","article-title":"Thapsigargin, a histamine secretagogue, is a non-12-O-tetradecanoylphorbol-13-acetate (TPA) type tumor promoter in two-stage mouse skin carcinogenesis","volume":"111","author":"H Hakii","year":"1986","journal-title":"J Cancer Res Clin Oncol"},{"key":"ref46","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1111\/1523-1747.ep12329592","article-title":"Thapsigargin induces rapid, transient growth inhibition and c-fos expression followed by sustained growth stimulation in mouse keratinocyte cultures","volume":"107","author":"CS Harmon","year":"1996","journal-title":"J Invest Dermatol"},{"key":"ref47","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.abb.2007.03.040","article-title":"Mechanisms of resistance and adaptation to thapsigargin in androgen-independent prostate cancer PC3 and DU145 cells","volume":"464","author":"DI Lee","year":"2007","journal-title":"Arch Biochem Biophys"},{"key":"ref48","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1006\/bbrc.1999.0891","article-title":"Characterization of novel inhibitors of cyclin-dependent kinases","volume":"260","author":"LL Kent","year":"1999","journal-title":"Biochem Biophys Res Commun"},{"key":"ref49","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1111\/j.1349-7006.2003.tb01371.x","article-title":"Characterization of cell death induced by ethacrynic acid in a human colon cancer cell line DLD-1 and suppression by N-acetyl-L-cysteine","volume":"94","author":"S Aizawa","year":"2003","journal-title":"Cancer Sci"},{"key":"ref50","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0304-3940(99)00107-X","article-title":"Differential effects of L-buthionine sulfoximine and ethacrynic acid on glutathione levels and mitochondrial function in PC12 cells","volume":"264","author":"J Seyfried","year":"1999","journal-title":"Neurosci Lett"},{"key":"ref51","doi-asserted-by":"crossref","first-page":"e8294","DOI":"10.1371\/journal.pone.0008294","article-title":"Ethacrynic acid exhibits selective toxicity to chronic lymphocytic leukemia cells by inhibition of the Wnt\/beta-catenin pathway","volume":"4","author":"D Lu","year":"2009","journal-title":"PLoS One"},{"key":"ref52","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1038\/bjc.1992.145","article-title":"A study of ethacrynic acid as a potential modifier of melphalan and cisplatin sensitivity in human lung cancer parental and drug-resistant cell lines","volume":"65","author":"T Rhodes","year":"1992","journal-title":"Br J Cancer"},{"key":"ref53","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1016\/S0022-3565(25)22526-5","article-title":"Pharmakokinetics and bioavailability study of ethacrynic acid as a modulator of drug resistance in patients with cancer","volume":"270","author":"FP Lacreta","year":"1994","journal-title":"J Pharmacol Exp Ther"},{"key":"ref54","first-page":"3622","article-title":"Ethacrynic acid and piriprost as enhancers of cytotoxicity in drug resistant and sensitive cell lines","volume":"48","author":"KD Tew","year":"1988","journal-title":"Cancer Res"},{"key":"ref55","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1002\/ptr.3074","article-title":"Pharmacokinetics of bilobalide, ginkgolide A and B after administration of three different Ginkgo biloba L. preparations in humans","volume":"24","author":"K Woelkart","year":"2010","journal-title":"Phytother Res"},{"issue":"Suppl 1","key":"ref56","first-page":"S8","article-title":"Pharmacological studies supporting the therapeutic use of Ginkgo biloba extract for Alzheimer&apos;s disease","volume":"36","author":"B Ahlemeyer","year":"2003","journal-title":"Pharmacopsychiatry"},{"key":"ref57","doi-asserted-by":"crossref","first-page":"107","DOI":"10.3390\/ijms11010107","article-title":"Ginkgo biloba extract in Alzheimer&apos;s disease: From action mechanisms to medical practice","volume":"11","author":"C Shi","year":"2010","journal-title":"Int J Mol Sci"},{"key":"ref58","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1097\/00029330-200705020-00013","article-title":"Pharmacological action and mechanisms of ginkgolide B","volume":"120","author":"SH Xia","year":"2007","journal-title":"Chin Med J (Engl)"},{"volume":"2006","key":"ref59","unstructured":"Aponte MM, Kwong J, Mok SC, Berkowitz RS, Cramer DW, <etal>et al<\/etal>.. (2006) Gingkolide may prevent ovarian cancer through the platelet activating factor receptor (PAFR) pathway. AACR Meeting Abstracts <volume>2006<\/volume>: : A106\u2013."},{"key":"ref60","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1097\/CEJ.0b013e328348fbb7","article-title":"Ginkgo may prevent genetic-associated ovarian cancer risk: multiple biomarkers and anticancer pathways induced by ginkgolide B in BRCA1-mutant ovarian epithelial cells","volume":"20","author":"W Jiang","year":"2011","journal-title":"Eur J Cancer Prev"},{"key":"ref61","article-title":"Ginkgo May Sensitize Ovarian Cancer Cells to Cisplatin: Antiproliferative and Apoptosis-Inducing Effects of Ginkgolide B on Ovarian Cancer Cells","author":"W Jiang","year":"2012","journal-title":"Integr Cancer Ther"},{"key":"ref62","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1046\/j.1472-8206.2003.00156.x","article-title":"Ginkgo biloba extracts and cancer: a research area in its infancy","volume":"17","author":"FV DeFeudis","year":"2003","journal-title":"Fundam Clin Pharmacol"},{"key":"ref63","first-page":"570","article-title":"Biological investigations of 6-azathymine, a thymine analog","volume":"14","author":"WH Prusoff","year":"1954","journal-title":"Cancer Res"},{"key":"ref64","first-page":"435","article-title":"[Clinical investigations of 6-azathymine: a thymine analog]","volume":"20","author":"RR Ellison","year":"1960","journal-title":"Cancer Res"},{"key":"ref65","first-page":"67","article-title":"Screening for epigenetically masked genes in colorectal cancer Using 5-Aza-2\u2032-deoxycytidine, microarray and gene expression profile","volume":"9","author":"A Khamas","year":"2012","journal-title":"Cancer Genomics Proteomics"}],"container-title":["PLoS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0086299","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T17:48:09Z","timestamp":1746121689000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0086299"}},"subtitle":[],"editor":[{"given":"Yu","family":"Xue","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2014,1,27]]},"references-count":65,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2014,1,27]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0086299","relation":{},"ISSN":["1932-6203"],"issn-type":[{"type":"electronic","value":"1932-6203"}],"subject":[],"published":{"date-parts":[[2014,1,27]]}}}